ValuEngine downgraded shares of Pain Therapeutics (NASDAQ:PTIE) from a sell rating to a strong sell rating in a research note released on Friday morning.

Separately, Zacks Investment Research cut Pain Therapeutics from a buy rating to a hold rating in a research report on Tuesday, September 19th.

Shares of Pain Therapeutics (NASDAQ PTIE) traded up $0.04 on Friday, hitting $4.06. The stock had a trading volume of 26,730 shares, compared to its average volume of 68,775. Pain Therapeutics has a 12-month low of $3.10 and a 12-month high of $9.31.

Pain Therapeutics (NASDAQ:PTIE) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.40) earnings per share for the quarter. sell-side analysts predict that Pain Therapeutics will post -2.2 EPS for the current year.

A hedge fund recently bought a new stake in Pain Therapeutics stock. Dimensional Fund Advisors LP acquired a new position in Pain Therapeutics, Inc. (NASDAQ:PTIE) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 59,989 shares of the biopharmaceutical company’s stock, valued at approximately $247,000. Dimensional Fund Advisors LP owned about 0.91% of Pain Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 36.16% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Pain Therapeutics (PTIE) Downgraded by ValuEngine to “Strong Sell”” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/12/02/pain-therapeutics-ptie-downgraded-by-valuengine-to-strong-sell.html.

About Pain Therapeutics

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Receive News & Ratings for Pain Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.